Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.
Actively Recruiting
Researchers are evaluating zongertinib, an oral HER2-targeted drug, to see if it can improve outcomes compared to standard adjuvant treatments in adults with completely removed Stage II to IIIB non-small cell lung cancer NSCLC that has activating HER2 tyrosine kinase domain mutations. This Phase 3, global, randomized, open-label study includes participants who have had surgery with curative intent and received perioperative systemic therapy such as neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomly assigned to one of two groups one group takes zongertinib daily by mouth for up to three years, while the other group follows standard care, which may include approved adjuvant immunotherapy or observation based on local guidelines and patient condition. This comparison aims to determine if zongertinib can extend disease-free survival. Safety, overall survival, tolerability, and patient-reported outcomes are also monitored during the study. During the study, participants undergo regular evaluations including disease assessments by investigators for up to 8 years and 5 months to measure disease-free survival and overall survival. Safety is tracked by recording adverse events, especially those of grade 3 or higher, from treatment start through up to three years or tumor recurrence. Participants provide tumor tissue samples for HER2 status confirmation, and their overall health and organ functions are monitored. The entire study lasts several years, including follow-up to assess long-term outcomes.
Actively Recruiting
Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.
Actively Recruiting
Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of LY4268989 combined with mirikizumab compared to mirikizumab alone in adults with moderately to severely active ulcerative colitis UC. This Phase 2, randomized, double-blind study focuses on treatment for UC, aiming to determine whether the combination improves clinical remission and response rates. Participants will receive either LY4268989 orally along with mirikizumab administered first intravenously then subcutaneously, or mirikizumab with a placebo oral treatment. Responders during the study will be re-randomized for a second study period. Treatment lasts approximately 104 weeks with up to 21 visits. Throughout the study, participants will attend regular visits for assessments including clinical remission status using the modified Mayo Score at weeks 12, 24, and 48, as well as endoscopic improvement and symptomatic remission. Safety and response to treatment will be monitored over about 118 weeks of total participation.
Actively Recruiting
Researchers are developing a registry of Brazilian patients with hereditary cardiovascular diseases by combining clinical information and genetic data. The study aims to identify which genes are most commonly affected and the frequency of these genetic changes within this population. The registry will help advance understanding and healthcare for hereditary heart conditions in Brazils public health system. Participants will be interviewed during their routine medical visits, and their DNA will be collected using buccal swabs for whole genome sequencing. This observational study does not involve any treatment but focuses on gathering detailed genetic and clinical data to better characterize hereditary cardiovascular diseases. The study is planned to run for 30 months starting from April 2025. During the study, participants will provide information through interviews and give DNA samples for sequencing. Researchers will measure diagnostic yield, genetic diversity, and variant frequency over the 30 months. The study does not involve additional interventions beyond data and sample collection, and participants will continue their usual medical care throughout the study period.
Actively Recruiting
Researchers are investigating the effects of a polypill combined with colchicine in people with established atherosclerotic cardiovascular disease ASCVD, a major cause of illness and death worldwide, including Brazil. The trial aims to assess whether this combination can better prevent heart and blood vessel events compared to usual care. The study addresses the need for improved control of cardiovascular risk factors and adherence to treatments in a diverse population. Participants will be randomly assigned to one of four groups cardiovascular polypill plus colchicine, cardiovascular polypill plus placebo, usual care plus colchicine, or usual care plus placebo. The polypill contains fixed doses of valsartan, atorvastatin, and aspirin, taken daily. Colchicine or its placebo is given once daily. The study will last about three years on average, with the goal of evaluating the combined effects of these treatments on cardiovascular health. During the study, participants will be monitored for major adverse cardiovascular and limb events, including heart attacks, strokes, and cardiovascular deaths. Researchers will collect data throughout the trial to assess treatment effects and safety. The study design includes a randomized, quadruple-masked approach to ensure unbiased results. Participants can expect regular evaluations over the study period, which ends around May 2031.
Actively Recruiting
Researchers are conducting a phase III, randomized, multi-center clinical trial to evaluate whether intravenous Tenecteplase TNK treatment is better than a placebo for patients who have suffered a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours after they were last seen well. The study focuses on patients with evidence of salvageable brain tissue or a clinical-radiological mismatch on perfusion imaging. The goal is to determine if TNK can improve functional outcomes compared to placebo. Participants will be randomly assigned in a 11 ratio to receive either a single intravenous bolus injection of Tenecteplase at a dose of 0.25 mgkg maximum 25 mg or a placebo bolus injection over 5 seconds. The study uses a double-blind design, and randomization considers factors such as age, stroke severity, and timing since last seen well. The planned enrollment is 466 participants, split evenly between the TNK and placebo groups, with interim analyses to assess study progress. During the 90-day follow-up, participants will undergo assessments including modified Rankin Scale scoring to evaluate functional outcomes, brain imaging to measure infarct volume and reperfusion, and quality of life questionnaires at 3 months, 6 months, and one year. Safety outcomes like intracranial hemorrhage and mortality rates will also be monitored. These evaluations aim to measure the effectiveness and safety of TNK treatment compared to placebo after ischemic stroke.
Actively Recruiting
Researchers are evaluating whether the drug zilebesiran can reduce major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults with hypertension that is not well controlled and who have either established cardiovascular disease or are at high risk for it. This is a phase 3, randomized, double-blind, placebo-controlled study that will continue until a targeted number of cardiovascular events have occurred. Participants will receive either 300 mg of zilebesiran or a placebo by subcutaneous injection every six months, in addition to their standard antihypertensive medications, which must include a thiazide, thiazide-like, or loop diuretic. The study involves two parallel groups one receiving the active drug and the other receiving placebo, both as add-on therapies to current treatment. During the trial, participants will be regularly monitored for cardiovascular outcomes over approximately five years. The main measurement is the time to the first occurrence of a composite endpoint including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure events requiring hospitalization or urgent visits. Blood pressure changes at six months and other cardiovascular outcomes will also be assessed. Safety and effectiveness will be closely observed throughout the study period.